Cytek Biosciences, Inc.CTKBNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank65
3Y CAGR-24.0%
5Y CAGR-28.6%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
-24.0%/yr
Quarterly compound
5Y CAGR
-28.6%/yr
Recent acceleration
Percentile
P65
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 80.22% |
| Q3 2025 | -3709.26% |
| Q2 2025 | 186.40% |
| Q1 2025 | -106.26% |
| Q4 2024 | -84.90% |
| Q3 2024 | 113.10% |
| Q2 2024 | 56.79% |
| Q1 2024 | -58.40% |
| Q4 2023 | 324.39% |
| Q3 2023 | -48.74% |
| Q2 2023 | -199.72% |
| Q1 2023 | -53.85% |
| Q4 2022 | 182.53% |
| Q3 2022 | 20.51% |
| Q2 2022 | -537.84% |
| Q1 2022 | -127.17% |
| Q4 2021 | 369.25% |
| Q3 2021 | 129.66% |
| Q2 2021 | -302.27% |
| Q1 2021 | -83.38% |
| Q4 2020 | 431.31% |
| Q3 2020 | 1910.74% |
| Q2 2020 | -108.37% |
| Q1 2020 | 0.00% |